Novo Nordisk Q4 2024 Results: Will Wegovy Continue to Shine?

Mitrade
coverImg
Source: DepositPhotos

TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.


These can help treat type 2 diabetes and obesity but one of the other astounding effects is that they help people lose weight as it slows down how quickly a person’s stomach empties – making them feel full for longer and, thus, ensuring they eat less.


Understandably, the purveyors of these drugs have been immensely profitable. One of the biggest producers of these GLP-1 drugs is Danish firm Novo Nordisk A/S (NYSE: NVO). The company is set to report its Q4 2024 earnings on Wednesday 5 February before the market opens in the US.


Here’s what investors should know going into the earnings release and what they should be looking out for.


Watching Wegovy and Ozempic growth


Both Wegovy and Ozempic are the key GLP-1 drugs for Novo Nordisk and investors will be eager to see how much progress the company has had in broadening the reach of these two weight loss drugs.


While Wegovy is the key weight-loss drug for Novo Nordisk, Ozempic is also a key contributor but is more targeted at treating type 2 Diabetes. 


In terms of its latest results, for Q3 2024, Novo Nordisk delivered revenue of DKK 71.3 billion (US$10.3 billion) for the period. That was up 21% year-on-year as sales of Wegovy drove broader growth, with the key GLP-1 drug posting sales that were up 79% year-on-year – at DKK 17.3 billion.


Meanwhile, Novo Nordisk’s Q3 2024 net profit hit DKK 27.3 billion and operating profit surged by 26% year-on-year to DKK 33.8 billion. 


Increasing supply – watch out for surprises


The insatiable demand for GLP-1 drugs has Novo Nordisk scrambling to increase production of its blockbuster drugs and the company has already established a clear lead in the market in terms of the share it owns.


Global number of patients on GLP-1s across diabetes and obesity

A graph of blue and white

AI-generated content may be incorrect.

Source: Novo Nordisk 9M 2024 earnings presentation


With a commanding volume market share of nearly two-thirds as of August 2024, Novo Nordisk added in its Q3 2024 earnings call that it’s looking to invest in capacity both internally and externally to increase supply – of Wegovy and Ozempic – in the short term and long term. 


If Novo Nordisk can post stronger-than-expected Wegovy and Ozempic sales for the final quarter of 2024 then the stock could see a positive reaction. Indeed, on the back of the company’s release of its Q3 2024 earnings, shares jumped nearly 8%.


Despite Novo Nordisk narrowing its full-year 2024 sales growth outlook during that call, to 23% to 27%, investors can be hopeful that the company will be able to beat those numbers given the overwhelming demand for its drugs. 


Indeed, it most likely comes down to the extent that the company was able to increase supply during the final quarter of 2024.


Is competition increasing?


Investors will also be keen to see how GLP-1 drugs from Eli Lilly & Co (NYSE: LLY) as the key peer reports just a day after Novo Nordisk, on Thursday 6 February.


Novo Nordisk’s dominant position in the US, though, looks set to continue as the company’s first nine months of 2024 saw its sales in North America increase by 31% year-on-year, largely driven by its GLP-1 drugs.


Despite the firm’s strong market position, its New York-listed ADRs are down over 22% in the past year amid worries over competitive pressures from Eli Lilly and a lack of supply for its key drugs. 


Whether the upcoming results, and management’s comments, can help convince investors to get more bullish on the stock remains to be seen.

Read more

  • Spot Gold Breaches Four Key Levels, Putting $3,500 at Risk as Technicals Enter Oversold Alert Zone
  • * The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

    goTop
    quote
    Related Articles
    placeholder
    TradingKey Daily Market Brief: Three Major US Indexes Drop Over 2%, Anthropic Gains 17% on DebutTracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
    Author  TradingKey
    Nov 20, Fri
    Tracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
    placeholder
    Nvidia posts record $115.8B Q3 revenue, but crypto stays mutedThe crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
    Author  FXStreet
    Nov 18, Wed
    The crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
    placeholder
    Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
    Author  TradingKey
    Nov 17, Tue
    As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
    placeholder
    Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    Author  Irene Q.
    Nov 16, Mon
    The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    placeholder
    Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    Author  Irene Q.
    Nov 16, Mon
    Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.

    US Stocks Related Articles

    • 10 Best Day Trading Platforms for Beginners and Active Traders in 2026: A Practical Guide
    • How To Invest in SpaceX Stock in 2026? Everything Investors Need to Know
    • Practice Trading Us Stocks? These Are 10 Best Stock Trading Demo Apps For Beginners
    • ​5 Best Paper Trading Platforms for 2026 (Free Demo Accounts for Beginners & Traders)
    • Wall Street’s Top 10 US Stocks for 2026 vs What Reddit Is Actually Buying
    • Is Mitrade Right for You? A Complete Guide on How to Start Trading CFDs in 5 Steps

    Click to view more